Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TOP1 | P11387 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | BHMT | Q93088 | 1/20 | 0.33 |
| ▸ | MVD | P53602 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27291406 | 0.81 | LMNA (0.58) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL27291420 | 0.81 | LMNA (0.58) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL21901457 | 0.81 | LMNA (0.58) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL25934670 | 0.81 | LMNA (0.58) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL18654191 | 0.80 | MVD (0.34) | BHMTMVD | |
| SCHEMBL32670449 | 0.80 | PDE4A (0.41) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL9789405 | 0.80 | PDE4A (0.48) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL14639905 | 0.78 | PDE4A (0.42) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL13026580 | 0.78 | PDE4A (0.42) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL6009532 | 0.78 | TYMP (0.38) | LMNAL3MBTL1TDP1KDM4EBHMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | PDE4A 4760/4885LMNA 4466/4885USP2 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.